Wir sind mit live! Mehr erfahren

Quanome Technologies

QNME

Börsenwert 17,9 Mio. $

0,5210 USD

-0,0481

8,45 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

0,5250

+0,0040

0,77 %

1 Tag

-8,45 %

5 Tage

-25,06 %

1 Monat

82,23 %

3 Monate

44,52 %

6 Monate

-42,2 %

Seit Jahresbeginn

-41,46 %

1 Jahr

-62,25 %

5 Jahre

-87,01 %

10 Jahre

-87,01 %

Profil: Quanome Technologies Inc operates in the midstream segment of the pharmaceutical industrial ecosystem, operating between upstream pharmaceutical manufacturers and downstream medical end customers. It sources products from multiple manufacturers and suppliers, and distribute them to hospitals, pharmaceutical distributors and other healthcare providers. Its principal product categories include infusion products, foods for special medical purposes, and specialty pharmaceuticals. It operates in one reportable segment serves its customers by providing pharmaceutical products in China. The company generates a substantial percentage of its revenue from selling pharmaceutical products on a direct basis.

Mitarbeiter: 27

Industrie Integrierte Fracht- und Logistikdienstleistungen

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 20 %

Neutral 80 %

Negativ 0 %

Quanome's XDT Secures First Enterprise Customer Agreement for Dedicated AI Inference Services

Initial 60-Month Order Has a Total Commitment Value Exceeding $100 Million; Service-Start Conditions Apply New York, NY, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Quanome Technologies, Inc. (Nasdaq: QNME) (“Quanome” or the “Company”) today announced that XDT Infrastructure I, LLC (“XDT”), an indirect wholly-owned subsidiary of Quanome, has entered into a Master Services Agreement and initial Order with an enterprise customer to provide dedicated artificial intelligence capacity. Under the initial Order, XDT will provide the customer with dedicated computing capacity to run its AI applications.

Quanome's XDT Secures First Enterprise Customer Agreement for Dedicated AI Inference Services

Quanome CEO to Back Quantum Strategy with Up to $15 Million in Non-Dilutive Growth Capital

Insider Scaled Capital Support Reflects Confidence in Quanome 's Strategic Direction and Future Potential

Quanome CEO to Back Quantum Strategy with Up to $15 Million in Non-Dilutive Growth Capital

Quanome Advances Its AI Cloud Business XDT with US$18.8 Million Infrastructure Purchase Agreement

Company Advances Development of First U.S. AI Infrastructure Hub, Executes Its Quantum & AI Systems Strategy

Quanome Advances Its AI Cloud Business XDT with US$18.8 Million Infrastructure Purchase Agreement

Quanome Stock Soars 80% After Agreeing to Buy 32 GPU Servers

Quanome Technologies Inc. (NASDAQ:QNME) shares are trading higher Tuesday after the company announced it entered into a Purchase and Sale Agreement and related purchase order with Compal Electronics for the purchase of 32 GPU server units.

Quanome Stock Soars 80% After Agreeing to Buy 32 GPU Servers

Quanome Technologies Establishes Global Quantum Council and Scientific Advisory Network

International expert platforms bring together scientific expertise across four quantum streams to advance understanding, collaboration and real-world application

Quanome Technologies Establishes Global Quantum Council and Scientific Advisory Network

Lakeside Announces Fiscal 2025 Third Quarter and Nine-Month Results

ITASCA, IL, May 15, 2025 (GLOBE NEWSWIRE) -- Lakeside Holding Limited (“Lakeside” or the “Company”) (Nasdaq: LSH), a U.S.-based cross-border supply chain solution provider with a unique focus on the Asia-Pacific market operating through two specialized subsidiaries—American Bear Logistics and Hupan Pharmaceutical (Hubei) Co., Ltd., today announced financial results for its fiscal 2025 third quarter and nine months ended March 31, 2025.

Lakeside Announces Fiscal 2025 Third Quarter and Nine-Month Results

LAKESIDE HOLDING ANNOUNCES A CONVERTIBLE DEBT FINANCING OF UP TO $4.5 MILLION

ITASCA, Ill. , March 5, 2025 /PRNewswire/ -- Lakeside Holding Limited ("Lakeside" or the "Company") (Nasdaq: LSH), a U.S.-based cross-border supply chain solution provider with a unique focus on the Asia-Pacific market operating through two specialized subsidiaries—American Bear Logistics and Hupan Pharmaceutical (Hubei) Co., Ltd.

LAKESIDE HOLDING ANNOUNCES A CONVERTIBLE DEBT FINANCING OF UP TO $4.5 MILLION

Lakeside Announces Fiscal 2025 Second Quarter and Six-Month Results

ITASCA, Ill. , Feb. 14, 2025 /PRNewswire/ -- Lakeside Holding Limited ("Lakeside" or the "Company") (Nasdaq: LSH), a U.S.-based cross-border supply chain solution provider with a unique focus on the Asia-Pacific market operating through two specialized subsidiaries—American Bear Logistics and Hupan Pharmaceutical (Hubei) Co., Ltd.

Lakeside Announces Fiscal 2025 Second Quarter and Six-Month Results

Lakeside Secures New Distribution Agreements with Kelun Pharmaceutical

Expanding Partnerships with Major Industry Players ITASCA, Ill. , Jan. 21, 2025 /PRNewswire/ -- Lakeside Holding Limited ("Lakeside" or the "Company") (Nasdaq: LSH), a U.S.-based cross-border supply chain solution provider with a unique focus on the Asia-Pacific market is pleased to announce that its wholly owned subsidiary, Hupan Pharmaceutical (Hubei) Co., Ltd.

Lakeside Secures New Distribution Agreements with Kelun Pharmaceutical

Lakeside Partners with Huiyu Pharmaceutical to Revolutionize Oncology Drug Distribution

ITASCA, Ill. , Jan. 7, 2025 /PRNewswire/ -- Lakeside Holding Limited ("Lakeside" or the "Company") (Nasdaq: LSH), a U.S.-based cross-border supply chain solution provider with a unique focus on the Asia-Pacific market today announced that Hupan Pharmaceutical has entered into a strategic distribution agreement with Sichuan Huiyu Pharmaceutical Co., Ltd.

Lakeside Partners with Huiyu Pharmaceutical to Revolutionize Oncology Drug Distribution

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt